SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/44A5EE1A79E0F804E06470F42C5780A224EE5621629B3A9F93F4EA3425328F4999FAC1B4A2B09B9A644F43C19931A9CF>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/44A5EE1A79E0F804E06470F42C5780A224EE5621629B3A9F93F4EA3425328F4999FAC1B4A2B09B9A644F43C19931A9CF
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/44A5EE1A79E0F804E06470F42C5780A224EE5621629B3A9F93F4EA3425328F4999FAC1B4A2B09B9A644F43C19931A9CF
http://www.w3.org/2000/01/rdf-schema#comment
"When compared with SET-NUP214-negative patients SET-NUP214-positive patients showed a significantly higher rate of corticosteroid resistance (91% vs 44%; P = .003) and chemotherapy resistance (100% vs 44%; P = .0001)."
xsd:string
http://purl.uniprot.org/uniprot/#_D0E78D5F20E6173219611E5D9233F820F48EEA5722F7696EAED8A4AA10458DA1815700E1150AA0BCE3D8BFD780F95236
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/44A5EE1A79E0F804E06470F42C5780A224EE5621629B3A9F93F4EA3425328F4999FAC1B4A2B09B9A644F43C19931A9CF
http://purl.uniprot.org/uniprot/Q5VXV3
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/44A5EE1A79E0F804E06470F42C5780A224EE5621629B3A9F93F4EA3425328F4999FAC1B4A2B09B9A644F43C19931A9CF
http://purl.uniprot.org/uniprot/#_Q5VXV3-mappedCitation-24449214
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/44A5EE1A79E0F804E06470F42C5780A224EE5621629B3A9F93F4EA3425328F4999FAC1B4A2B09B9A644F43C19931A9CF